therapeutic-depth biosimilars 
Pharmaceutical Technology
AUGUST 26, 2022
Novartis has announced plans to completely spin off its generics and biosimilars division, Sandoz, to create a new publicly traded standalone firm. The latest development is intended to increase shareholder value by establishing a top European generics firm and a leader in biosimilars internationally.
Pharmaceutical Technology
DECEMBER 9, 2022
Research and development highlights from the research period include the company’s work with Mirati Therapeutics in developing methods to determine torsion rotational energy barriers of the clinical compound, MRTX1719, which is being developed for use as an inhibiter to MTAP-deleted cancers. Biopharmaceutical analytical services. Switzerland.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Channels
OCTOBER 10, 2023
Drug Distribution Industry Gaining from Anti-Obesity Drugs and Provider-Administered Biosimilars (press release) We’re offering special discounted pricing if you order before October 20, 2023! which examines the distribution of COVID-19 vaccines and therapeutics. pharmaceutical distribution industry. and Section 6.4.3.
Pharmaceutical Technology
SEPTEMBER 26, 2022
The company told GlobalData PharmSource: “The biosimilar facilities in Austria and Slovenia would continue to manufacture biosimilars for Sandoz under a contractual agreement with Novartis. This came after an attempted sell-off starting last October was met with no formal offers from a buyer.
The Pharma Data
OCTOBER 29, 2020
An international CRO with over 15 years’ experience, we offer fully integrated services performing all aspects of clinical trials in all clinical phases and in a wide range of therapeutic areas. Expertise in innovative, generics and biosimilar global studies (NDAs, ANDAs, BLAs, 505b2).
The Pharma Data
MAY 6, 2021
ENVI calls on the Commission to “revise the use of supplementary protection certificates based on technological and scientific advances to prevent generic and biosimilar medicines from becoming less competitive inside and outside the EU.”. . The restriction will apply for two years. . EMA Report. .
The Pharma Data
JANUARY 26, 2021
Through its three businesses – Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Dr. Reddy’s operates in markets across the globe.
Expert insights. Personalized for you.
147 
Let's personalize your content